HOME >> BIOLOGY >> NEWS
JCI table of contents -- April 19, 2007

EDITOR'S PICK

Why cisplatin kills breast cancer cells when other drugs fail

The cancerous cells of some individuals with breast cancer lack expression of two cell surface proteins, the estrogen and progesterone receptors, and do not express increased amounts of HER2. Individuals with such breast cancer (known as triple-negative breast cancer) do not respond to treatment with commonly used chemotherapeutic drugs and their prognosis is relatively poor. But now, a new study from researchers at Massachusetts General Hospital Cancer Center, Boston, has indicated that triple-negative breast cancer cell lines are sensitive to exposure to the chemotherapeutic cisplatin.

In the study, which appears online on April 19 in advance of publication in the May print issue of the Journal of Clinical Investigation, Leif Ellisen and colleagues show that triple-negative breast cancer specimens express increased amounts of two proteins, delta-Np63 and TAp73. Delta-Np63 was shown to bind TAp73 and prevent it from killing the cancerous cells. Importantly, the chemotherapeutic drug cisplatin, but not other commonly used chemotherapeutic drugs, was found to release TAp73 from delta-Np63, causing the cells to be killed. This study indicates that individuals with triple-negative breast cancer might benefit from early treatment with cisplatin if their cancerous cells express increased amounts of delta-Np63 and TAp73.

TITLE: The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers

AUTHOR CONTACT:

Leif W. Ellisen
Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 726-4315; Fax: (617) 726-8623; E-mail: ellisen@helix.mgh.harvard.edu.

Sue McGreevey
Massachusetts General Hospital Public Affairs, Boston, Massachusett
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
19-Apr-2007


Page: 1 2 3 4 5 6 7

Related biology news :

1. Antioxidant overload may underlie a heritable human disease
2. JCI table of contents: Aug. 9, 2007
3. JCI table of contents: August 1, 2007
4. US Department of Defense awards $1.6 million for implantable biochip research
5. More fish oil, less vegetable oil, better for your health
6. JCI table of contents -- July 26, 2007
7. JCI table of contents: July 19, 2007
8. JCI table of contents: July 12, 2007
9. JCI table of contents: June 21, 2007
10. JCI table of contents: June 14, 2007
11. Food safety begins as vegetables grow

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/24/2017)... MILAN , March 24, 2017 The Controller ... Deputy Controller Mr. Abdulla Algeen have received the prestigious international ... Continue Reading ... ... small picture) and Deputy Controller Abdulla Algeen (small picture on the right) ...
Breaking Biology News(10 mins):
(Date:8/11/2017)... (PRWEB) , ... August 11, 2017 , ... Algenist continues ... collagen-based formulation unlocking collagen like never before. , Collagen is the key structural ... to market with Liquid Collagen™, which include: , First ...
(Date:8/10/2017)... NC (PRWEB) , ... August 09, 2017 , ... Each ... Almost half never recover well enough to live an independent lifestyle and, even worse, ... , A new discovery by doctors at the University of California Davis Medical Center ...
(Date:8/10/2017)... ... August 10, 2017 , ... CNA ... outlet had initiated coverage on Next Group Holdings, Inc. and see's significant opportunity ... geared toward those that cannot engage in traditional banking services. According to industry ...
(Date:8/8/2017)... ... August 08, 2017 , ... Cynvenio Biosystems, Inc. ... announced the launch of its second generation PD-L1 expression test. The new blood ... highly sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer ...
Breaking Biology Technology:
Cached News: